Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Special Report
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. Originally Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the last trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott Laboratories’ situation suggests a possible disconnect between market sentiment and operational reality. The key question for long-term investors is whether the market’s pessimism is justified or whether a significant value opportunity has emerged. Separating the Signal From the NoiseAbbott’s recent decline stems from two distinct pressures. The first is an internal headwind in its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, primarily from market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has acknowledged the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described price and promotion initiatives and a pipeline of at least eight new product launches in 2026 intended to reignite volume growth, with a return to growth expected in the second half of the year. The second factor is broader and external. The market has been rotating capital away from defensive sectors like healthcare and into higher-beta areas such as artificial intelligence (AI) and the energy sector during periods of economic optimism. This broad trend has put pressure on many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment works toward recovery, Abbott’s core businesses remain robust—led by its largest and most profitable division, Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model helps offset the isolated weakness in Nutrition, and the company’s strength is most apparent in these high-performing areas.
Medical Devices: The Medical Devices business is firing on multiple cylinders, driven by market-leading innovation in critical care and procedural areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors continues to be a major growth driver. By enabling glucose tracking without routine fingersticks, the franchise generated over $7.5 billion in sales in 2025 and remains central to Abbott’s long-term growth story. Cardiovascular Leadership: Abbott is also a leader in cardiovascular care. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. This performance is supported by best-in-class products such as MitraClip and TriClip, which provide minimally invasive heart valve repair, and a pipeline of innovations including the recently FDA-approved Volt PFA System for atrial fibrillation. Abbott is also making strategic moves to secure future growth, most notably through the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for the non-invasive colon cancer test Cologuard. That deal would position Abbott immediately as a major player in the expanding, multi-billion-dollar market for cancer diagnostics, adding a new high-growth vertical that could contribute meaningfully to revenue for years to come. This bullish view is not just internal—Wall Street also favors the stock. Analysts maintain a Moderate Buy consensus rating, with an average 12-month price target of $135.47, implying upside of roughly 30% from current levels and suggesting many pros believe the stock is undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is a standout feature. Abbott is a member of the S&P 500 Dividend Kings, a rare group of companies that have raised their dividend for at least 50 consecutive years. That track record underscores a long-term commitment to returning capital to shareholders across market cycles. The recent drop in Abbott’s stock price has a direct, positive effect for new investors: a higher dividend yield. At current levels, Abbott yields about 2.5%, offering a more attractive entry yield from a historically reliable payer. The dividend appears secure—its payout is roughly 68% of earnings and about 37% of cash flow—indicating Abbott generates ample cash to cover distributions with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott seems out of step with its business fundamentals. Temporary headwinds in a single division, combined with sector-wide capital rotation, have weighed on the stock price. Yet Abbott’s core growth engines—especially Medical Devices—are accelerating, the dividend remains solid, and strategic catalysts like the Exact Sciences acquisition could add meaningful long-term growth. For investors with a multi-year horizon, the present valuation appears to offer a noteworthy gap between market price and fundamental value that deserves consideration. |
